Skip to main content
NTRA
NASDAQ Life Sciences

Signatera Shows 100% PPV vs 62% for PET/CT in Lymphoma MRD Study

Tom Rudovsky · Reported by BusinessWire
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$323.3
Mkt Cap
$46.409B
52W Low
$157.425
52W High
$343.18
52W Position info
105% above low
Off High info
5.8% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

NTRA has more than doubled off its 52-week low of $157.425.

Summary

A new publication in Blood Neoplasia validates Signatera for MRD assessment in lymphoma, showing it outperforms PET/CT. In a 144-patient study across 14 subtypes, Signatera at end of treatment had a hazard ratio of 80.83 for event-free survival versus 5.18 for PET/CT, and a positive predictive value of 100% versus 62%. Signatera clearance during first-line therapy and after CAR-T was associated with significantly better outcomes. This strengthens the clinical case for Signatera in a new indication and supports the recent NCCN guideline update recommending ctDNA-based MRD assessment. The data could accelerate adoption in lymphoma, expanding Natera's oncology market beyond its current solid tumor focus.

At the time of this announcement, NTRA was trading at $323.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.4B. The 52-week trading range was $157.43 to $343.18. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

NTRA - Latest Insights

NTRA
Nov 06, 2026, 11:25 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $316.02
Real-time Price: $294.00 info
Change: -$22.02 (-7%) info
Market Cap: $41.979B info
NTRA
Nov 05, 2026, 4:49 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $293.97
Real-time Price: $294.00 info
Change: +$0.0262 (+0.01%) info
Market Cap: $41.979B info
NTRA
Nov 05, 2026, 4:06 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $366.75
Real-time Price: $294.00 info
Change: -$72.75 (-20%) info
Market Cap: $41.979B info
NTRA
Nov 05, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $363.76
Real-time Price: $294.00 info
Change: -$69.76 (-19%) info
Market Cap: $41.979B info
NTRA
Nov 03, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $380.77
Real-time Price: $294.00 info
Change: -$86.77 (-23%) info
Market Cap: $41.979B info